Memphis Pharmaceuticals & Chemical Industries (EGX:MPCI)
Egypt · Delayed Price · Currency is EGP 298.24
-4.06 (-1.34%)
At close: Oct 22, 2026
EGX:MPCI Income Statement
Financials in millions EGP. Fiscal year is July - June.
Millions EGP. Fiscal year is Jul - Jun.
Fiscal Year | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Jun '25 Jun 30, 2025 | Jun '24 Jun 30, 2024 | Jun '23 Jun 30, 2023 | Jun '22 Jun 30, 2022 |
Operating Revenue | 1,706 | 1,508 | 871.91 | 663.83 | 551.26 |
| 1,706 | 1,508 | 871.91 | 663.83 | 551.26 | |
Revenue Growth | 13.14% | 72.93% | 31.34% | 20.42% | 6.40% |
Cost of Revenue | 1,024 | 824.02 | 571.62 | 450.88 | 401.87 |
Gross Profit | 682.18 | 683.78 | 300.29 | 212.95 | 149.39 |
Selling, General & Admin | 113.86 | 99.02 | 86.19 | 77.41 | 71.8 |
Other Operating Expenses | 44.88 | 42.24 | 2.69 | 39.65 | 8.55 |
Operating Expenses | 158.74 | 141.25 | 88.88 | 117.06 | 80.35 |
Operating Income | 523.43 | 542.53 | 211.41 | 95.89 | 69.04 |
Interest Expense | -26.72 | -13.51 | -14.26 | - | - |
Interest & Investment Income | 101.61 | 136.47 | 55.65 | 11.13 | 7.28 |
Currency Exchange Gain (Loss) | -2.61 | -20.18 | - | - | 0.67 |
Other Non Operating Income (Expenses) | 5.16 | 6.99 | -23.29 | 2.96 | 1.34 |
EBT Excluding Unusual Items | 600.87 | 652.3 | 229.52 | 109.98 | 78.32 |
Pretax Income | 600.87 | 652.3 | 229.52 | 109.98 | 78.32 |
Income Tax Expense | 120.91 | 147.02 | 38.06 | 19.55 | 4.23 |
Net Income | 479.96 | 505.28 | 191.46 | 90.44 | 74.09 |
Net Income to Common | 479.96 | 505.28 | 191.46 | 90.44 | 74.09 |
Net Income Growth | -5.01% | 163.91% | 111.70% | 22.07% | 77.22% |
Shares Outstanding (Basic) | 23 | 23 | 6 | 6 | 6 |
Shares Outstanding (Diluted) | 23 | 23 | 6 | 6 | 6 |
Shares Change | -0.06% | 304.63% | - | - | - |
EPS (Basic) | 21.10 | 22.20 | 34.04 | 16.08 | 13.17 |
EPS (Diluted) | 21.10 | 22.20 | 34.04 | 16.08 | 13.17 |
EPS Growth | -4.96% | -34.78% | 111.70% | 22.07% | - |
Additional Metrics
Fiscal Year | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Jun '25 Jun 30, 2025 | Jun '24 Jun 30, 2024 | Jun '23 Jun 30, 2023 | Jun '22 Jun 30, 2022 |
Free Cash Flow | 185.39 | 65.65 | 158.83 | 46.49 | 23.55 |
Free Cash Flow Per Share | 8.15 | 2.88 | 28.24 | 8.27 | 4.19 |
Dividend Per Share | 13.187 | 13.187 | 4.000 | 2.000 | - |
Dividend Growth | 0% | 229.67% | 100.00% | - | - |
Gross Margin | 39.99% | 45.35% | 34.44% | 32.08% | 27.10% |
Operating Margin | 30.68% | 35.98% | 24.25% | 14.45% | 12.52% |
Profit Margin | 28.13% | 33.51% | 21.96% | 13.62% | 13.44% |
Free Cash Flow Margin | 10.87% | 4.35% | 18.22% | 7.00% | 4.27% |
EBITDA | 544.79 | 562.35 | 223.59 | 103.65 | 76.68 |
EBITDA Margin | 31.94% | 37.30% | 25.64% | 15.61% | 13.91% |
D&A For EBITDA | 21.36 | 19.82 | 12.18 | 7.75 | 7.64 |
EBIT | 523.43 | 542.53 | 211.41 | 95.89 | 69.04 |
EBIT Margin | 30.68% | 35.98% | 24.25% | 14.45% | 12.52% |
Effective Tax Rate | 20.12% | 22.54% | 16.58% | 17.77% | 5.40% |